tirzepatide and retatrutide together + Peptide | Research Grade Retatrutide vs. Tirzepatide: Dual vs.

Diem, Ducluzeau, Scheen)

Clinical Trial Results The clinical trial SURMOUNT-5 (NCT05822830) of adults with obesity who did not have type 2 diabetes demonstrated that Zepbound patients had an average weight loss of 50.3 lbs (22.8 kg), which was 20.2% of their body weight, and a 7.2-inch ( 18.4 cm) reduction in waist circumference, at 72 weeks

Researchers seeking a detailed catalogue of the preclinical publications underpinning these findings are directed to the Retatrutide Evidence Dossier

Factors That May Influence Your Ideal Dosing Time Your side effect pattern, daily routine, and comorbidities particularly type 2 diabetes managed with insulin or sulfonylureas are the key factors in choosing the most appropriate retatrutide injection time

You start low

When reconstituted, it should be stored refrigerated at 2-8 degrees C and protected from light